3BBLACKBIO
3B Blackbio Dx share price & financials
- Price
- ₹1,196.1
- Market cap
- ₹1.2k Cr
- Sector
- Healthcare
Quarterly results
Q1 FY27: revenue up 15.0%, net profit up 16.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27 | 23 | 23 | 20 | 28 +4% | 24 +4% | 25 +9% | 23 +15% |
| EBITDA | 15 | 15 | 9 | 12 | 16 +7% | 14 −7% | 11 +22% | 13 +8% |
| Net profit | 14 | 13 | 9 | 12 | 15 +7% | 14 +8% | 7 −22% | 14 +17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +0.7% 1Y
1Y: ₹1,410.35 on 10 Sept 2025 → ₹1,419.9. High ₹1,695.75 (16 Jan 2026), low ₹1,120.6 (5 Jun 2026).
Financials, as filed
Revenue grew 16.9% a year over 2 years, FY24 to FY26. Operating margin widened to 54.6%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹71 Cr | ₹91 Cr | ₹97 Cr |
| Operating profit | ₹36 Cr | ₹49 Cr | ₹53 Cr |
| Operating margin | 50.7% | 53.8% | 54.6% |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net profit | ₹33 Cr | ₹47 Cr | ₹48 Cr |
| Net margin | 46.5% | 51.6% | 49.5% |
| Cash from operations | ₹28 Cr | ₹44 Cr | ₹43 Cr |
| Free cash flow | ₹28 Cr | ₹44 Cr | ₹41 Cr |
| ROCE | 22.0% | 26.0% | 22.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹7 Cr | ₹7 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr |
| Reserves | ₹15 Cr | ₹16 Cr | ₹188 Cr | ₹219 Cr | ₹290 Cr | ₹310 Cr |
| Borrowings | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr |
| Other liabilities | ₹4 Cr | ₹5 Cr | ₹16 Cr | ₹21 Cr | ₹42 Cr | ₹31 Cr |
| Total liabilities | ₹29 Cr | ₹32 Cr | ₹214 Cr | ₹250 Cr | ₹341 Cr | ₹350 Cr |
| Fixed assets | ₹2 Cr | ₹3 Cr | ₹7 Cr | ₹7 Cr | ₹17 Cr | ₹7 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹4 Cr | ₹4 Cr | ₹102 Cr | ₹128 Cr | ₹160 Cr | ₹188 Cr |
| Other assets | ₹23 Cr | ₹25 Cr | ₹105 Cr | ₹116 Cr | ₹163 Cr | ₹155 Cr |
| Total assets | ₹29 Cr | ₹32 Cr | ₹214 Cr | ₹250 Cr | ₹341 Cr | ₹350 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs added +0.39 pp while promoters trimmed −0.33 pp. The shareholder count grew 4% to 11,049.
- Promoters
- 41.0%
- FIIs
- 2.5%
- DIIs
- 2.1%
- Public
- 54.4%
Since Jun 2025
- DIIs +0.39 pp
- Promoters −0.33 pp
- FIIs −0.20 pp
How it drifted, 12 quarters
Over this window the public fell from 57.6% to 54.4% — −3.2 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 38.4%, FIIs 3.2%, DIIs 0.8%, Public 57.6%.Dec '23: Promoters 38.4%, FIIs 3.4%, DIIs 1.2%, Public 57.0%.Mar '24: Promoters 41.3%, FIIs 3.0%, DIIs 1.9%, Public 53.9%.Jun '24: Promoters 41.3%, FIIs 3.3%, DIIs 2.0%, Public 53.5%.Sep '24: Promoters 41.3%, FIIs 3.3%, DIIs 2.0%, Public 53.5%.Dec '24: Promoters 41.3%, FIIs 2.7%, DIIs 1.7%, Public 54.3%.Mar '25: Promoters 41.3%, FIIs 2.5%, DIIs 1.6%, Public 54.6%.Jun '25: Promoters 41.3%, FIIs 2.7%, DIIs 1.8%, Public 54.3%.Sep '25: Promoters 41.3%, FIIs 2.6%, DIIs 1.8%, Public 54.3%.Dec '25: Promoters 41.3%, FIIs 2.6%, DIIs 1.9%, Public 54.3%.Mar '26: Promoters 40.9%, FIIs 2.6%, DIIs 2.0%, Public 54.5%.Jun '26: Promoters 41.0%, FIIs 2.5%, DIIs 2.1%, Public 54.4%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Rashi Daga +0.09 pp 5.62% held
The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of 3B Blackbio Dx Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Mithla Dubey | 12.35% | unchanged |
| Mithala Laboratories Private Limited | 9.56% | unchanged |
| Dhirendra Dubey | 8.45% | unchanged |
| Rashi Daga | 5.62% | +0.09 pp |
| Prateek Goel | 5.14% | unchanged |
| Own Infracon Private Limited | 4.41% | unchanged |
| Nikhil Kuber Dubey | 4.17% | unchanged |
| Maj Navraj Singh Grewal | 2.65% | unchanged |
| 2B Blackbio S.L. Spain | 2.48% | unchanged |
| Ram Kuber Dhirendra Kumar | 2.27% | unchanged |
| Ark Global Emerging Companies, Lp FPI fund | 1.94% | unchanged |
| Dalmus Performance Focused Fund AIF | 1.87% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
ExpensiveTo justify its price of ₹1420, this stock must grow earnings at 20% every year for 7 years. Our analysis caps realistic growth at ~16%. At that growth it is worth ₹1181 — downside of 17%.
- Growth the price implies
- 19.8% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 20.6% a year
- net profit, FY24–FY26 · EPS 16.2%
- The gap
- 0.0 pp
- -17% downside if it only repeats history
Learn to analyse 3B Blackbio Dx Limited
Guides on how to read this kind of business and the numbers that matter.